Novartis and AbbVie sue Washington to block new 340B drug pricing law
Novartis and AbbVie filed suit to block Washington's new 340B drug pricing law before it takes effect in June, claiming tens of millions in unrecoverable losses.
Drug companies sue Washington over new pricing law. (Photo by Eric Thayer/Getty Images)
(Photo by Eric Thayer/Getty Images)
Two of the world’s biggest drug companies are suing Washington state just as a new law to rein in prescription prices is set to take effect. Novartis and AbbVie filed lawsuits on Wednesday, arguing that a plan signed by Governor Bob Ferguson won’t actually help patients save money, it will only hurt the companies’ profits.
Senate Bill 5981, a Democrat-led measure that split Republicans in the House, aims to protect the federal 340B program. This program is a lifeline for several local clinics and rural hospitals. Since 1992, the federal government has required drug makers to give huge discounts sometimes up to 60% off to “safety-net” hospitals that serve low-income or rural communities.
How Washington’s 340B drug discount law works
According to Washington State Standard, the system works as a financial boost by allowing hospitals to buy drugs at a deep discount and then bill insurance companies for those same medications at the full market rate. The hospitals are then able to keep the difference in price to fund vital services, such as mental health care or chronic disease treatment, for patients who otherwise wouldn’t be able to afford it.
Because many small clinics don’t have their own pharmacies, they partner with outside drugstores to get the medicine to patients. This is where the fight starts. Drug companies have been trying to limit these partnerships, claiming that hospitals and big pharmacy chains are just using the program to “pad their profits” instead of helping the poor.
Washington’s new law stops drug companies from telling hospitals which pharmacies they can use. It also prevents companies from demanding extra data from hospitals as a “condition” for getting the discounted medications.
Novartis and AbbVie push back — and say it will cost them millions
Governor Ferguson, who signed the bill despite pressure from companies like Pfizer and AstraZeneca, says the law is about transparency. “This will allow the state to have more insight into improving the program to ensure it supports providers while, most importantly, protecting consumers,” Ferguson said, per Washington State Standard.
Novartis and AbbVie aren’t going down without a fight. In their lawsuits, they claim the law will cost them tens of millions of dollars in “unrecoverable” losses. They argue that Washington is overstepping and interfering with federal law.
While drug companies have won some court cases regarding these pharmacy restrictions in the past, other states like Arkansas and Mississippi have seen similar laws upheld. Governor Ferguson says he is confident the state can defend the law in court. For now, both companies are asking a judge to block the law before it officially starts this June.
Follow Seattle Red on-air at 770 AM, on the Seattle Red app, and streaming audio and video on SeattleRed.com.






Comments
0 Comments